CHK1 gene encodes for a serine/threonine kinase involved in the regulation of cell cycle progression and DNA damage checkpoints. To determine the role of CHK1 in the pathogenesis of lymphoid neoplasms and its relationship to other DNA damage response genes, we have analyzed the gene status, protein, and mRNA expression in a series of tumors and nonneoplastic lymphoid tissues. CHK1 protein and mRNA expression levels were very low in both reactive tissues and resting lymphoid cells, whereas tumor samples showed a variable pattern of expression related to their proliferative activity. However, seven aggressive tumors showed a dissociate pattern of extremely low or negative protein expression in spite of a high proliferative activity. Four of these tumors were diffuse large B-cell lymphomas (DLCLs) with concordant reduced levels of mRNA, whereas one blastoid mantle cell lymphoma (B-MCL) and two DLCLs had relatively normal levels of mRNA. No gene mutations, deletions, or hypermethylation of the promoter region were detected in any of these cases. In all these tumors ATM, CHK2, and p53 genes were wild type. These findings suggest that CHK1 inactivation in NHLs occurs by loss of protein expression in a subset of aggressive variants alternatively to ATM, CHK2, and p53 alterations.
Introduction
Lymphoid neoplasms are a heterogeneous group of disease entities characterized by distinctive clinical, morphologic, immunophenotypical, and genetic features. 1 Chromosomal instability is also a characteristic feature of these tumors and is associated with aggressive disease course and poor prognosis of the patients. [2] [3] [4] The molecular mechanisms involved in this genetic instability are not well known. Recent studies have shown the presence of alterations in the DNA damage response pathways in malignant lymphomas and its possible association with the genetic instability of the tumors. 2, 3, [5] [6] [7] [8] [9] [10] [11] CHK1 gene encodes for a serine/threonine kinase that, similarly to the functionally related CHK2, is involved in the signal transduction mechanisms of the DNA damage response pathways in response to the activation of upstream kinases. In mammals, CHK1 is mainly regulated by the ATR kinase, although it also collaborates with CHK2 in response to ionizing radiation induced-DNA damage as a downstream effector of ATM. Activated CHK1 phosphorylates and regulates different downstream targets, such as p53 and CDC25 phosphatases, promoting cell cycle arrest at G1/S and G2/M boundaries after DNA damage, and also S phase delay and inhibition of replication origin firing when DNA replication is blocked. 12 The potential role of CHK1 gene in the pathogenesis of human cancer is not well known. Different studies have shown CHK1 frameshift mutations in endometrial, colorectal, and stomach carcinomas with microsatellite instability. [13] [14] [15] However, the presence of CHK1 alterations in human lymphomas and the possible relationship with the inactivation of other elements of the DNA damage response pathways has not been previously examined.
In this study we have examined CHK1 gene status and mRNA and protein expression in a series of NHLs and its relationship to the status of p53, CHK2, and ATM genes. Our results indicate that CHK1 inactivation in NHLs occurs by loss of protein expression in a subset of aggressive variants alternatively to ATM, CHK2, and p53 alterations.
Materials and methods

Case selection
Tumor specimens from 74 non-Hodgkin's lymphomas (NHLs) were obtained from the Department of Pathology of the Hospital Clinic, University of Barcelona, on the basis of the availability of frozen samples for molecular studies. These tumors included 14 chronic lymphocytic leukemias (CLL), four large B-cell lymphomas transformed from CLL (Richter's syndrome, (RS)), 12 typical mantle cell lymphomas (T-MCL), 10 blastoid variants of mantle cell lymphomas (B-MCL), 10 follicular lymphomas (two grade 1, eight grade 2), and 24 primary diffuse large B-cell lymphomas (DLCL). The selected cases had a predominance of tumor cells with less than 5-10% normal or reactive cells. Follicular lymphomas had a higher number of reactive cells mainly of Tcell phenotype. The series of non-neoplastic lymphoid samples, including six tonsils, four reactive lymph nodes, two spleens, and six samples of normal peripheral blood lymphocytes (PBLs), were also examined. A subset of the tumors included in the study had been previously examined for CHK2, p53, and ATM gene alterations. Chromosomal imbalances had been also analyzed by comparative genomic hybridization (CGH). 2, 3, 6, 11, 16 Tumors lacking this information in which CHK1 appeared to be altered were additionally examined by CGH and for CHK2, and p53 gene alterations and protein expression as previously described. 2, 3, 11, 16 Given that ATM gene mutations are virtually always associated with allelic deletions in mantle cell lymphoma and large B-cell lymphomas, 6, 7, 17 the ATM allelic dosage was examined in these cases by quantitative PCR as described previously. 18 
RNA extraction and reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was obtained from frozen tissues using guanidine isothiocyanate extraction and cesium chloride gradient centrifugation. cDNA was synthesized from 1 mg of total RNA using random hexamers (TaqMan reverse transcription reagents, Applied Biosystems, Warrington, UK) and following the manufacturer's specifications. The CHK1 complete coding region was amplified by PCR in nine partly overlapping portions using the primers and PCR conditions previously described 19 (Supplementary material Table I ).
Single-stranded conformation polymorphism (SSCP) and sequencing analysis SSCP analysis was used to screen for CHK1 mutations in the complete coding region using the nine overlapping cDNA fragments obtained by RT-PCR and the methodology previously described. 20 Products with an altered mobility were direct sequenced. To examine the frequency of Val471Ile change in normal population, DNA obtained from 50 healthy Spanish blood donors was subjected to PCR-SSCP using the following conditions: 35 cycles at 941C for 40 s, 561C for 40 s, and 721C for 40 s. PCR amplifications were performed using CHK1 primers flanking the genomic region in which Val471Ile variant was located (Supplementary material Table I ). These PCR products were analyzed using a SSCP strategy as described above.
Methylation-specific polymerase chain reaction (MSP)
The methylation status of the CHK1 CpG island was analyzed using the MSP technique. 21 The DNA region of interest was amplified with primer pairs specific for methylated vs unmethylated DNA (Supplementary material Table I ). Placental DNA methylated in vitro with SssI bacterial methylase and normal lymphocytes were used as positive and negative control for methylation, respectively. Some of these PCR products were sequenced to ensure the fidelity of the technique.
Real-time quantitative PCR analysis of CHK1 gene CHK1 gene has been mapped to 11q22-q24, approximately 17 Mb more telomeric than ATM gene. 22, 23 This chromosomal region is frequently lost in lymphoid neoplasms, particularly in CLL and MCL. 2, 3 A quantitative real-time PCR assay was used to assess the genomic copy number of the CHK1 gene. Sequences of the CHK1 detection probe and primers were designed using the Primer Express software (Applied Biosystems) (Supplementary material Table I ). The quantitative assay amplified 20 ng of DNA as template in two to four replicates as described. 11 As lymphoid malignancies usually showed complex karyotypes, we used two genes as endogenous controls: b 2 -microglobulin, and albumin, as previously described. 24, 25 CHK1 levels were related to the signal of the endogenous control genes in each case and amplification levels of DNA obtained from normal samples were used as controls. DNA obtained from cases with known trisomy and monosomy 11 were used to optimize the technique in order to detect single copy gains and losses, respectively (Supplementary material Table II) .
Real-time quantitative RT-PCR
A total of 1 mg of total RNA treated with DNAse was transcribed into cDNA using MMLV-reverse transcriptase (BRL, Gaithersburg, MD, USA) and random hexamers, following the manufacturer's directions. PCR reactions were performed using 2 ml of the final product of the previous reaction and the same CHK1 primers, CHK1 probe and conditions described above. The bglucuronidase gene (GUS, Applied Biosystems) was used as endogenous control as recommended by the manufacturer. GUS and CHK1 expression was related to a standard curve derived from serial dilutions of a cDNA from tonsil sample. The relative units (RU) of CHK1 expression was defined as the mRNA level of this gene normalized to the GUS expression level in each case. An RNA mix obtained from 7 non-neoplastic lymphoid tissues (two tonsils, two reactive lymph nodes, one spleen, and two PBLs) was used as reference control to normalize CHK1/ GUS amplification ratios.
Protein extraction and Western blot analysis
Nuclear protein extracts were obtained from 66 tumors and 18 non-neoplastic tissues as described. 11 In addition, protein extracts obtained from 12 non-neoplastic lymphoid tissues and six samples of normal PBLs were also analyzed. The blocked membranes were incubated with the monoclonal antibody anti-CHK1 (sc-8408, Santa Cruz Biotechnologies, Santa Cruz, CA, USA). A monoclonal antibody anti-a-tubulin (Santa Cruz Biotechnologies) was used as a loading control. Antibody binding was detected by chemoluminiscence detection procedures according to the manufacturer's recommendations (ECL; Amersham, Little Chalfont, UK). Intensities of the CHK1 proteins were quantified and normalized to the a-tubulin signal in each case using the Image-Gauge version 4.0 software (Fuji Photo Film Co., Ltd).
Immunohistochemistry
The proliferation rate of tumors was assessed by immunohistochemical quantification of Ki-67 antigen expression on formaldehyde-fixed, paraffin embedded material as described. 26 
Statistical analysis
Comparison between mRNA expression levels in different groups of NHLs, and between chromosomal imbalances and inactivation of CHK1, CHK2, ATM, and p53 was performed using the Kruskal-Wallis test. To determine whether CHK1 mRNA expression levels could correlate with protein expression and tumor proliferation, a regression analysis was assessed. The level of significance was set at 0.05 for all analysis and all calculations were performed with the SPSS software package (SPSS, version 10.0).
Results
CHK1 gene analysis
The entire coding region of the CHK1 gene was screened for gene mutations in 53 NHLs (eight CLLs, nine FLs, seven T-MCLs, eight B-MCLs, 17 DLCLs, and four RS). A different mobility shift was detected in one CLL, one FL, one T-MCL, and three DLCLs.
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Sequencing analysis demonstrated that this mobility corresponded to an heterozygous CHK1 variant at codon 471 (GTT to ATT), which leads to a valine to isoleucine substitution ( Figure 1a) . Thus, the frequency of this allele in this series was 5.7%. To determine if the Val471Ile substitution was present in Spanish cancer-free population we screened 100 alleles from 50 healthy blood donors. The results showed that this variant was present in five samples (one homozygous and four heterozygous), which corresponded to an allelic frequency of 6%, similar to that found in tumors (Figure 1b) .
To determine if CHK1 could be deleted in human lymphomas, we studied 25 tumors (three CLLs, three FLs, six T-MCLs, three B-MCLs, seven DLCLs, and three RS) by genomic real-time quantitative PCR, including all samples in which protein expression levels were found decreased by Western blot (see below) and three tumors with 11q loss detected by CGH. Owing to the relative proximity of CHK1 and ATM genes, we analyzed also the possible allelic deletions of the ATM gene in these three cases. In two of these three tumors we detected an allelic ATM gene deletion. However, all lymphoid tumors showed CHK1/ b2-microglobulin, and albumin amplification ratios similar to those found in normal PBLs and non-neoplastic tissues, indicating that CHK1 gene is not commonly deleted in human lymphoid neoplasms.
To determine if the decreased protein expression detected in these cases could be caused by promoter hypermethylation of the gene, an MSP study was performed in 10 lymphoid tumors, including all samples with CHK1 decreased protein expression, and one reactive tonsil. The results showed no evidence of CHK1 promoter hypermethylation in any of the samples analyzed ( Figure 2 and Supplementary material Figure I ).
CHK1 mRNA expression
CHK1 mRNA expression was examined in 65 tumors (nine CLLs, 10 FLs, 12 typical MCLs, 10 blastoid MCLs, 20 DLCLs, and four RS). Non-neoplastic lymphoid samples, including two tonsils, two reactive lymph nodes, one spleen, and two samples of PBLs were also analyzed. A variable pattern of CHK1 mRNA expression was observed in the different types of lymphoid neoplasms. The highest levels of CHK1 mRNA expression were detected in the more aggressive and high proliferating variants of NHLs, such as B-MCLs, DLCLs, and RS, whereas non-neoplastic samples showed low levels of expression (Figure 3a 
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To determine if the different levels of CHK1 mRNA expression detected in NHLs could be related to the proliferation rate of the tumors, samples were immunostained for the proliferation marker Ki-67. A regression analysis of CHK1 mRNA expression and proliferation activity of the tumors was performed in 49 cases and showed a statistically significant correlation between these parameters (Figure 3b ; r ¼ 0.53, Po0.001). These results indicate that CHK1 mRNA expression levels are related to the proliferation activity of human malignant lymphomas.
During the course of the RT-PCR analysis for CHK1 gene mutations we detected the occasional presence of a shorter transcript. Sequencing analysis of this PCR product demonstrated that this transcript corresponded to a previously described CHK1 isoform present in small cell lung carcinomas. 19 To determine whether this transcript could be associated with malignant lymphomas, we analyzed by RT-PCR 60 tumors and seven non-neoplastic lymphoid samples. We detected this transcript in five lymphomas, but it was also present in four of the non-neoplastic lymphoid tissues analyzed. The reason for the apparent higher frequency of the shorter transcript in the non-neoplastic tissues is unknown, but may be due to the relative lower number of cases examined.
Protein expression
CHK1 protein expression was examined in 66 NHLs (14 CLLs, four RS, 14 MCLs, 10 FLs, and 24 DLCLs), and in a series of 12 non-neoplastic lymphoid tissues and six samples of normal PBLs. Very low levels of protein expression were detected in both reactive tissues and PBLs. Tumors showed a variable pattern of protein expression related to the proliferation activity and the mRNA levels of the neoplasms (Figure 4a, b) . Thus, we found nine tumors with very low proliferation rate (Ki-67 ¼ 1071%) that had also very low levels of mRNA and protein expression. In contrast, 25 tumors with high proliferative activity (Ki-67 ¼ 37725%) showed strong protein expression and higher levels of mRNA expression. Moreover, a regression analysis showed a statistically significant association between mRNA and protein expression levels (r ¼ 0.48, P ¼ 0.003; Supplementary material Figure III) . However, we identified seven aggressive and high proliferating tumors (Ki-67 ¼ 54714%) with a discordant pattern of extremely low or negative protein expression. Three of these tumors (one B-MCL and two DLCLs) had relatively normal levels of mRNA, whereas the other four tumors (one RS and three DLCLs) showed very low levels of mRNA in spite of their high proliferation rate. (Figure 4b ; Table 1 
Figure 4
Western blot analysis of CHK1 protein expression in NHLs and non-neoplastic lymphoid tissues. (a) Normal lymphoid tissues showed low levels of CHK1 protein whereas the majority of tumors had high levels of protein expression. A subset of aggressive and highly proliferative lymphomas showed very low or absent CHK1 protein expression. Levels of a-tubulin in the same samples were used as loading controls are shown in the bottom panel. (b) Tumors with low or absent CHK1 protein expression showed low proliferative activity and also low levels of mRNA expression. Samples with positive CHK1 protein expression had higher levels of both proliferative activity and mRNA. A subset of seven highly proliferative lymphomas had loss of CHK1 protein expression, three of them expressed normal levels of mRNA according to their proliferation rate, whereas four additional tumors had abnormally reduced RNA expression levels, similar to those observed in low proliferating lymphomas. 1q22q31, 7q21q22, 18 ). CGH results are described according to the ISCN nomenclature; rev ish refers to in situ hybridization, enh (enhanced) and dim (diminished) indicate gains or losses of chromosomal material in the indicated region and amp refers to amplification. Cases with decreased protein expression and abnormally reduced mRNA levels in relation to the proliferative activity of the tumors.
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respectively, including all tumors with CHK1 inactivation. Interestingly, all lymphomas with loss of CHK1 protein expression showed no alterations in the ATM, p53, and CHK2 genes. Chromosomal imbalances had been analyzed by CGH in 43 tumors. The B-MCL with CHK1 inactivation had 12 chromosomal imbalances, a similar number to that found in other B-MCLs with ATM, CHK2 and/or p53 inactivation (1174.5, mean7s.d.), and much higher than in cases with wild type CHK1, CHK2, ATM, and p53 (4.572.9). In contrast, the five DLCLs with CHK1 loss of protein expression showed a low number of chromosomal aberrations (171.2), and were similar to tumors with wild type p53, and CHK2 (271.9).
Discussion
In this study we have analyzed CHK1 gene status and both protein and mRNA expression in a large series of human lymphoid tumors and non-neoplastic samples. The unique gene variant found in our study was the previously described Val471Ile substitution. This CHK1 variant was also present in normal cancer-free blood donors in a similar percentage to that found in malignant lymphomas. These results agree with previous studies in Finnish population, suggesting that this nucleotide change is a relatively common polymorphism that may not be related to increased cancer risk. 27 CHK1 gene mutational status has been examined in a few number of tumor types. These studies have identified only frameshift mutations in endometrial, colorectal, and stomach carcinomas with microsatellite instability. [13] [14] [15] Although these mutations predict for truncated CHK1 protein, their pathogenetic significance is not clear since they have been always found as heterozygous aberrations. The lack of these type of mutations in lymphoid tumors is concordant with the uncommon finding of microsatellite alterations in these tumors. 28 All these observations indicate that gene mutation is not a relevant mechanism to inactivate CHK1 in human lymphomas.
CHK1 gene has been mapped to chromosome 11q22-23 and 11q24, more telomeric than the ATM gene. 22, 23 Cytogenetic studies in NHLs had detected frequent losses of the 11q22-23 chromosomal region, particularly in CLL and MCL.
2,3 However, we have not found CHK1 gene deletions in any of the samples analyzed, including cases with ATM gene deletion, indicating that ATM rather than CHK1 may be the target gene of these deletions. These results agree with a previous study in lung carcinoma, where CHK1 gene was neither mutated nor deleted by Southern blot. This study also showed that the unique potential CHK1 alteration in human lung carcinomas was the expression of an alternative CHK1 transcript associated with aggressive tumors. 19 This shorter isoform lacks exon 8, a domain predicted to be involved in substrate selectivity. However, the functional impact of this variant has not been elucidated. In our study, we have detected this CHK1 isoform in some tumors but also in non-neoplastic lymphoid tissues, suggesting that, contrary to lung tumors, this transcript may not play a relevant role in the pathogenesis of lymphoid neoplasms.
CHK1 mRNA and protein expression has been previously analyzed in human cancer cells as well as in normal fibroblasts. 29, 30 However, the CHK1 expression patterns have not been examined in human tumors. In contrast to the nonoscillating pattern of CHK2 expression during cell cycle phases, CHK1 mRNA and protein levels showed an S-G2 restricted pattern. 30 In that sense, our study demonstrates that CHK1 mRNA expression correlates with the proliferative activity in human lymphomas. Moreover, CHK1 protein expression correlated with the mRNA levels and this was concordant with the low or absent levels of CHK1 protein detected in nonneoplastic lymphoid samples and in a subset of lymphomas with low proliferative activity. On the other hand, lymphoid tumors with strong CHK1 protein expression showed higher mRNA levels and proliferative activity. These results suggest that CHK1 mRNA and protein expression in lymphoid neoplasms may be regulated, at least in part, by proliferation dependent mechanisms. In contrast with these findings, we have shown recently that CHK2 protein and mRNA expression levels are relatively similar in all types of NHLs independently of their proliferative rate, indicating that, in spite of their overlapping roles in DNA damage checkpoints, CHK1 and CHK2 expression may have different cell cycle related regulatory mechanisms. 11 Interestingly, a subset of seven aggressive tumors showed a marked decrease or complete absence of protein expression in spite of their high proliferative activity. Four of these tumors showed concomitant very low levels of mRNA, whereas three cases had mRNA levels concordant with their proliferative activity. The lack of gene mutations, deletions, or promoter hypermethylation suggests that the decreased protein expression in these tumors may be due to alterations in both transcriptional repression and post-transcriptional mechanisms regulating the stability of the protein. Although it has been recently reported that p53 downregulates the promoter activity of CHK1 gene, no p53 alterations were detected in any of these tumors. 31 The CHK1 gene is an important regulatory element in the DNA damage checkpoint. Several studies have now demonstrated that alterations in other genes involved in these pathways, such as p53, ATM, and CHK2, are associated with increasing levels of chromosomal instability in human lymphomas.
2,3,6,9,11 Interestingly, similarly to CHK2, CHK1 protein may be directly phosphorylated and activated by the upstream kinase ATM after DNA damage. 32, 33 In addition, experimental studies using mutant constructs have shown that inactivation of the CHK1 yeast homologue in Saccharomyces cerevisiae resulted in an increased rate of chromosomal abnormalities in a similar way to that found for CHK2. 34 However, the possible role of CHK1 in the maintenance of chromosomal integrity in human tumors is not known. In this study we identified a B-MCL with CHK1 decreased protein expression and ATM, p53, and CHK2 in apparent germ line, which showed a high number of chromosomal alterations similar to cases with inactivation of ATM, CHK2 and/or p53, and much higher than other B-MCLs with these genes in germ-line. On the contrary, DLCLs cases with CHK1 inactivation had similar number of genomic aberrations than those found in cases with wild-type p53 and CHK2, indicating that at least in these tumors CHK1 may not be a key element in the maintenance of genomic integrity. These findings suggest that the DNA damage response genes may contribute differentially in the maintenance of chromosomal stability in the different types of lymphomas.
In conclusion, our findings indicate that CHK1 gene inactivation is an uncommon phenomenon in human lymphomas, but it occurs by loss of protein expression alternatively to ATM, CHK2, and p53 gene alterations in a subset of aggressive lymphomas.
